Article
Pre-clinical evaluation of quinoxaline-derived chalcones in tuberculosis.
PloS one - 1 Jan 2018
Muradás Thaís C, Abbadi Bruno L, Villela Anne D, Macchi Fernanda S, Bergo Pedro F, de Freitas Talita F, Sperotto Nathalia D M, Timmers Luis F S M, Norberto de Souza Osmar, Picada Jaqueline N, Fachini Jean, da Silva Juliana Bondan, de Albuquerque Nayara C P, Habenschus Maísa D, Carrão Daniel B, Rocha Bruno A, Barbosa Junior Fernando, de Oliveira Anderson R M, Mascarello Alessandra, Neuenfeldf Patrícia, Nunes Ricardo J, Morbidoni Héctor R, Campos Maria M, Basso Luiz A, Rodrigues-Junior Valnês S
Abstract excerpt
New effective compounds for tuberculosis treatment are needed. This study evaluated the effects of a series of quinoxaline-derived chalcones against laboratorial strains and clinical isolates of M. tuberculosis. Six molecules, namely N5, N9, N10, N15, N16, and N23 inhibited the growth of the M. tuberculosis H37Rv laboratorial strain. The three compounds (N9, N15 and N23) with the lowest MIC values were further...
Topics
- Antitubercular Agents
- Bacterial Proteins
- Catalase
- Chalcones
- Cytochrome P-450 CYP2C19
- Cytochrome P-450 CYP2C9
- Cytochrome P-450 CYP3A
- Cytochrome P-450 Enzyme System